Drugs Affecting Blood and Blood Formation Practice Questions

Q: What is the mechanism of action of Dabigatran?

Direct inhibition of thrombin. **Explanation:** **Correct Answer: B. Direct inhibition of thrombin** Dabigatran etexilate is an oral, reversible, **Direct Thrombin Inhibitor (DTI)** [1], [2]. Unlike heparin, which requires antithrombin III as a cofactor, Dabigatran binds directly to the active site of both free and clot-bound thrombin (Factor IIa) [1], [2]. By inhibiting thrombin, it prevents the conversion of fibrinogen to fibrin, thereby blocking the final step of the coagulation cascade. **Analysis of Incorrect Options:** * **A. Activation of plasmin:** This is the mechanism of **Thrombolytics** (e.g., Streptokinase, Alteplase), which convert plasminogen to plasmin to dissolve existing clots. * **C. Indirect inhibition of thrombin:** This describes **Unfractionated Heparin (UFH)** and **Low Molecular Weight Heparins (LMWH)**. They act indirectly by accelerating the activity of Antithrombin III [3]. * **D. Inactivation of vitamin K dependent factors:** This is the mechanism of **Warfarin**, which inhibits Vitamin K Epoxide Reductase (VKOR), preventing the synthesis of Factors II, VII, IX, and X. **High-Yield NEET-PG Pearls:** * **Prodrug Status:** Dabigatran etexilate is a prodrug converted by esterases to its active form, Dabigatran [1], [2]. * **Monitoring:** Routine monitoring (like PT/INR) is not required, but **aPTT** can be used to assess its effect in emergencies [2]. * **Specific Antidote:** **Idarucizumab** (a humanized monoclonal antibody fragment) is the specific reversal agent for Dabigatran. * **Excretion:** It is primarily eliminated by the **kidneys**; thus, it is contraindicated in severe renal impairment [1]. * **Clinical Use:** Primarily used for stroke prevention in non-valvular atrial fibrillation and treatment of DVT/PE [1].

Q: What is the anticoagulant of choice in pregnancy?

Heparin. **Explanation:** **Heparin** (both Unfractionated Heparin and Low Molecular Weight Heparin) is the anticoagulant of choice in pregnancy because it has a high molecular weight and is highly polar, meaning it **does not cross the placenta**. Consequently, it poses no risk of teratogenicity or fetal hemorrhage. Low Molecular Weight Heparin (LMWH), such as Enoxaparin, is generally preferred over Unfractionated Heparin (UFH) due to a better safety profile, predictable pharmacokinetics, and lower risk of Heparin-Induced Thrombocytopenia (HIT) and osteoporosis. **Why the other options are incorrect:** * **Warfarin (Option B):** It is a small molecule that readily crosses the placenta. It is teratogenic, especially during the first trimester (6–9 weeks), leading to **Fetal Warfarin Syndrome** (characterized by nasal hypoplasia and stippled epiphyses). In the third trimester, it increases the risk of fetal intracranial hemorrhage. * **Dicoumarol and Phenindione (Options C & D):** These are oral anticoagulants similar to Warfarin. They cross the placenta and are associated with significant fetal risks, making them contraindicated in pregnancy. **High-Yield Clinical Pearls for NEET-PG:** * **Exception for Warfarin:** It may be used in pregnant women with **mechanical heart valves** (especially if the dose is <5mg/day) because the risk of valve thrombosis with Heparin is very high, though it must be switched to Heparin near term. * **Monitoring:** UFH is monitored using **aPTT**, whereas LMWH usually does not require monitoring (if needed, **Anti-Xa levels** are used). * **Labor Management:** Anticoagulants must be discontinued before labor to prevent maternal hemorrhage and to allow for regional anesthesia (epidural).

Q: Heparin acts by activation of which substance?

Antithrombin III. ### Explanation **Mechanism of Action (Why C is correct):** Heparin is an indirect-acting anticoagulant. It works by binding to **Antithrombin III (AT-III)**, a natural plasma protease inhibitor. This binding induces a conformational change in AT-III, accelerating its activity by nearly 1,000-fold. The Heparin-AT-III complex then inactivates several clotting factors, most notably **Thrombin (Factor IIa)** and **Factor Xa**, as well as factors IXa, XIa, and XIIa. By neutralizing these factors, heparin prevents the conversion of fibrinogen to fibrin, thereby inhibiting clot formation. **Analysis of Incorrect Options:** * **A & D (Plasmin/Fibrinolysin):** These are synonymous terms for the enzyme responsible for degrading existing fibrin clots. Heparin prevents *clot formation* (anticoagulant) but does not dissolve *existing clots* (thrombolytic). * **B (TPA):** Tissue Plasminogen Activator is a thrombolytic agent used to convert plasminogen into plasmin. It is used in acute MI or stroke, whereas heparin is used for prophylaxis or to prevent further propagation of a thrombus. **NEET-PG High-Yield Pearls:** * **Monitoring:** The efficacy of Unfractionated Heparin (UFH) is monitored using **aPTT** (intrinsic pathway). Low Molecular Weight Heparin (LMWH) usually does not require monitoring but can be checked using **Factor Xa levels**. * **Antidote:** The specific antidote for heparin overdose is **Protamine Sulfate** (a basic drug that neutralizes acidic heparin via ion pairing). * **Side Effects:** The most unique side effect is **Heparin-Induced Thrombocytopenia (HIT)**, caused by antibodies against the Heparin-Platelet Factor 4 complex. * **LMWH vs. UFH:** LMWH (e.g., Enoxaparin) mainly inactivates Factor Xa and has better bioavailability and a longer half-life compared to UFH.

Q: A patient is taking aspirin. What is the expected laboratory finding?

Prolonged bleeding time (BT). **Explanation:**1. Why Option A is Correct:Aspirin is an irreversible inhibitor of the enzyme **Cyclooxygenase-1 (COX-1)**. By acetylating the active site of COX-1 in platelets, it prevents the synthesis of **Thromboxane A2 (TXA2)**, a potent platelet aggregator and vasoconstrictor. [1, 3] Since platelets are anucleated and cannot synthesize new enzymes, this effect lasts for the entire lifespan of the platelet (approx. 7–10 days). [1, 3] **Bleeding Time (BT)** is a clinical measure of platelet function and primary hemostasis; therefore, inhibiting platelet aggregation directly leads to a prolonged BT. [1, 2]2. Why Other Options are Incorrect:* **Options B & C (PT and APTT):** These tests measure the integrity of the coagulation cascade (secondary hemostasis). PT assesses the extrinsic/common pathways, while APTT assesses the intrinsic/common pathways. Aspirin affects platelet aggregation, not the synthesis or activity of clotting factors.* **Option D (Clotting Time):** Clotting time is a crude measure of the coagulation cascade (specifically the intrinsic pathway). It remains normal in patients taking antiplatelet drugs like aspirin because the fibrin formation process is unaffected.3. High-Yield Clinical Pearls for NEET-PG:* **Low-dose Aspirin (75–150 mg):** Selective for COX-1 (Antiplatelet effect). [3]* **High-dose Aspirin:** Inhibits both COX-1 and COX-2 (Anti-inflammatory effect). [3]* **Surgery Protocol:** Aspirin should ideally be stopped **7 days prior** to major surgery to allow for the generation of new, functional platelets. [1, 3]* **Differentiate:** While Aspirin increases BT, [1] **Warfarin** increases PT/INR, and **Heparin** increases APTT.

Q: Which of the following drugs is used in sickle cell anemia?

Hydroxyurea. **Explanation:** **Hydroxyurea** is the drug of choice for the prevention of painful vaso-occlusive crises in patients with sickle cell anemia. Its primary mechanism of action involves the **induction of Fetal Hemoglobin (HbF)** synthesis. HbF inhibits the polymerization of deoxygenated Hemoglobin S (HbS), thereby preventing the sickling of red blood cells, reducing hemolysis, and improving microvascular blood flow. Additionally, it reduces the expression of adhesion molecules on neutrophils and reticulocytes, further decreasing vascular occlusion. **Analysis of Incorrect Options:** * **Carmustine (BCNU):** A nitrosourea alkylating agent used primarily in the treatment of brain tumors (due to its ability to cross the blood-brain barrier) and lymphomas. It has no role in hemoglobin modulation. * **Paclitaxel:** A microtubule stabilizer (taxane) used in the treatment of ovarian, breast, and lung cancers. It acts by inhibiting mitosis, not by affecting erythropoiesis. * **Bleomycin:** An antitumor antibiotic that causes DNA strand breaks. It is used in Hodgkin lymphoma and testicular cancer but is notoriously associated with pulmonary fibrosis. **High-Yield NEET-PG Pearls:** * **Mechanism:** Hydroxyurea inhibits the enzyme **Ribonucleotide Reductase**, which converts ribonucleotides to deoxyribonucleotides (S-phase specific). * **Other Indications:** Chronic Myeloid Leukemia (CML), Polycythemia Vera, and Essential Thrombocythemia. * **Side Effects:** The dose-limiting toxicity is **bone marrow suppression** (leukopenia, anemia, thrombocytopenia). It is also potentially teratogenic. * **Other drugs in Sickle Cell:** **Voxelotor** (prevents HbS polymerization by increasing oxygen affinity) and **Crizanlizumab** (P-selectin inhibitor).

Q: Blood level of which clotting factor declines most rapidly after the initiation of warfarin therapy?

Factor VII. **Explanation:** Warfarin acts as a competitive inhibitor of the enzyme **Vitamin K Epoxide Reductase (VKOR)** [4]. This inhibition prevents the γ-carboxylation of glutamate residues on Vitamin K-dependent clotting factors (**II, VII, IX, and X**) and anticoagulant proteins (C and S), rendering them inactive [3]. The clinical effect of warfarin is not immediate; it depends on the **half-life** of the clotting factors already circulating in the plasma [1]. The factor with the shortest half-life will be depleted first. 1. **Factor VII (Correct):** It has the shortest half-life (approximately **4–6 hours**) [1]. Therefore, its levels decline most rapidly after starting warfarin, leading to an initial prolongation of the Prothrombin Time (PT/INR). 2. **Factor IX (Incorrect):** It has an intermediate half-life of approximately 24 hours [1]. 3. **Factor X (Incorrect):** It has an intermediate half-life of approximately 36–48 hours [1]. 4. **Prothrombin/Factor II (Incorrect):** It has the longest half-life (approximately **60–72 hours**) and is the last to decline [1]. **High-Yield Clinical Pearls for NEET-PG:** * **The "C" before "II" Rule:** Protein C also has a very short half-life (~8 hours) [2]. Because Protein C (an anticoagulant) disappears faster than Factors II and X (procoagulants), a temporary **hypercoagulable state** occurs. This is why "Heparin bridging" is mandatory to prevent **Warfarin-induced skin necrosis**. * **Monitoring:** Warfarin therapy is monitored using **PT/INR** (extrinsic pathway), while Heparin is monitored using **aPTT** (intrinsic pathway). * **Antidote:** For immediate reversal of warfarin, use **Fresh Frozen Plasma (FFP)** or Prothrombin Complex Concentrate (PCC). For non-emergent reversal, use **Vitamin K1 (Phytonadione)**.

Q: Desmopressin acts on ______ receptors to increase the release of VWF and factor VIII from endothelium?

V2. **Explanation:** Desmopressin (dDAVP) is a synthetic analogue of Vasopressin (ADH) with a modified structure that increases its selectivity and duration of action. **Why V2 is Correct:** Vasopressin receptors are G-protein coupled receptors. While **V2 receptors** are primarily known for their role in the renal collecting ducts (mediating water reabsorption via Aquaporin-2), they are also located on **vascular endothelial cells**. Stimulation of these extra-renal V2 receptors triggers the exocytosis of Weibel-Palade bodies, leading to the release of **von Willebrand Factor (vWF)** and **Factor VIII**. This makes Desmopressin a first-line treatment for mild Hemophilia A and von Willebrand Disease (Type 1). **Why other options are incorrect:** * **V1 (V1a):** These receptors are located on vascular smooth muscle. Their activation causes **vasoconstriction** and increases peripheral resistance. Desmopressin has minimal V1 activity compared to natural Vasopressin, which is why it does not cause significant hypertension. * **V3 (V1b):** These are found in the **anterior pituitary**, where they mediate the release of ACTH. * **V4:** There is no clinically recognized V4 receptor in human pharmacology related to vasopressin. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** Desmopressin can be given intranasally, IV, or orally. * **Drug of Choice (DOC):** Central Diabetes Insipidus and Nocturnal Enuresis. * **Side Effect:** The most serious side effect is **dilutional hyponatremia**, which can lead to seizures. * **Tachyphylaxis:** Repeated doses can lead to a diminished response due to the depletion of endothelial stores of vWF.

Q: The drug Vorapaxar acts by primarily inhibiting platelet aggregation caused by which of the following substances?

Thrombin. **Explanation:** **Vorapaxar** is a novel antiplatelet agent that acts as a competitive, selective, and reversible antagonist of the **Protease-Activated Receptor-1 (PAR-1)**. PAR-1 is the primary receptor for **Thrombin** on human platelets. Thrombin is the most potent activator of platelets; by blocking this receptor, Vorapaxar inhibits thrombin-induced platelet aggregation without interfering with thrombin’s ability to convert fibrinogen to fibrin (clot formation). **Analysis of Incorrect Options:** * **A. Thromboxane:** Thromboxane A2 (TXA2) synthesis is inhibited by **Aspirin** (via COX-1 inhibition). * **B. ADP:** Adenosine Diphosphate (ADP) receptors (P2Y12) are the targets of drugs like **Clopidogrel, Prasugrel, and Ticagrelor**. * **D. Prostacyclin:** This is a potent endogenous inhibitor of platelet aggregation (anti-thrombotic). Inhibiting it would promote, rather than prevent, aggregation. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** Vorapaxar is used for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). * **Pharmacokinetics:** It has a very long half-life (approx. 8 days), making its effects essentially irreversible in clinical practice. * **Contraindication:** It is strictly contraindicated in patients with a history of **Stroke, TIA, or Intracranial Hemorrhage** due to a significantly increased risk of bleeding. * **Metabolism:** It is metabolized by **CYP3A4**; thus, co-administration with strong CYP3A4 inhibitors or inducers should be avoided.

Q: Which drug binds to and inhibits the Gp IIb/IIIa glycoprotein, thereby causing platelet antiaggregatory effects?

Tirofiban. **Explanation:** **Correct Option: D. Tirofiban** The final common pathway of platelet aggregation involves the activation of the **Glycoprotein (Gp) IIb/IIIa receptor**. Once activated, this receptor binds to fibrinogen, which acts as a bridge between adjacent platelets. **Tirofiban** (along with Eptifibatide and Abciximab) is a specific Gp IIb/IIIa inhibitor. By binding to this receptor, it prevents fibrinogen cross-linking, thereby exerting a potent antiaggregatory effect. It is primarily used in Acute Coronary Syndromes (ACS) and during Percutaneous Coronary Intervention (PCI). **Incorrect Options:** * **A. Clopidogrel:** This is a P2Y12 receptor antagonist. It works by inhibiting the ADP-mediated pathway of platelet activation, not the Gp IIb/IIIa receptor directly. * **B. Enoxaparin:** This is a Low Molecular Weight Heparin (LMWH). It acts as an anticoagulant by accelerating the inhibition of Factor Xa (and to a lesser extent, Factor IIa) by antithrombin III. * **C. Fondaparinux:** This is a synthetic pentasaccharide that acts as a selective Factor Xa inhibitor. It has no direct effect on platelet receptors. **NEET-PG High-Yield Pearls:** * **Abciximab** is a chimeric monoclonal antibody against Gp IIb/IIIa; unlike Tirofiban, its binding is non-competitive and irreversible. * **Glanzmann Thrombasthenia** is a congenital bleeding disorder caused by a deficiency or dysfunction of the Gp IIb/IIIa receptor. * **Monitoring:** Unlike Heparin (aPTT) or Warfarin (PT/INR), Gp IIb/IIIa inhibitors do not require routine coagulation monitoring, but platelet counts should be checked to monitor for drug-induced thrombocytopenia.

Question 1

What is the mechanism of action of Dabigatran?

Accepted Answer

Direct inhibition of thrombin

Answer

Activation of plasmin

Answer

Indirect inhibition of thrombin

Answer

Inactivation of vitamin K dependent factors

Question 2

What is the anticoagulant of choice in pregnancy?

Accepted Answer

Heparin

Answer

Warfarin

Answer

Dicoumarol

Answer

Phenindione

Question 3

Heparin acts by activation of which substance?

Accepted Answer

Antithrombin III

Answer

Plasmin

Answer

TPA (Tissue Plasminogen Activator)

Answer

Fibrinolysin

Question 4

A patient is taking aspirin. What is the expected laboratory finding?

Accepted Answer

Prolonged bleeding time (BT)

Answer

Prolonged prothrombin time (PT)

Answer

Prolonged activated partial thromboplastin time (APTT)

Answer

Prolonged clotting time (CT)

Question 5

Warfarin acts by inhibiting the activation of all the following factors except:

Accepted Answer

Factor III

Answer

Factor VII

Answer

Factor IX

Answer

Factor X

Question 6

Which of the following drugs is used in sickle cell anemia?

Accepted Answer

Hydroxyurea

Answer

Carmustine

Answer

Paclitaxel

Answer

Bleomycin

Question 7

Blood level of which clotting factor declines most rapidly after the initiation of warfarin therapy?

Accepted Answer

Factor VII

Answer

Factor X

Answer

Prothrombin

Answer

Factor IX

Question 8

Desmopressin acts on ______ receptors to increase the release of VWF and factor VIII from endothelium?

Accepted Answer

V2

Answer

V1

Answer

V3

Answer

V4

Question 9

The drug Vorapaxar acts by primarily inhibiting platelet aggregation caused by which of the following substances?

Accepted Answer

Thrombin

Answer

Thromboxane

Answer

ADP

Answer

Prostacyclin

Question 10

Which drug binds to and inhibits the Gp IIb/IIIa glycoprotein, thereby causing platelet antiaggregatory effects?

Accepted Answer

Tirofiban

Answer

Clopidogrel

Answer

Enoxaparin

Answer

Fondaparinux

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?